Thymosin Alpha 1 laboratory research focuses on an N-terminally acetylated 28-amino acid peptide derived from prothymosin alpha. Investigated primarily for its interactions with pattern recognition receptors and T-cell maturation signaling pathways, this peptide serves as a vital reagent in cellular immunology and preclinical research. PX1 Research provides analytical-grade Thymosin Alpha 1 strictly synthesized for non-clinical laboratory applications.
Thymosin Alpha 1 laboratory research focuses on an N-terminally acetylated 28-amino acid peptide derived from prothymosin alpha. Investigated primarily for its interactions with pattern recognition receptors and T-cell maturation signaling pathways, this peptide serves as a vital reagent in cellular immunology and preclinical research. PX1 Research provides analytical-grade Thymosin Alpha 1 strictly synthesized for non-clinical laboratory applications.
Thymosin Alpha 1 laboratory research evaluates a 28-amino acid peptide synthesized to study mammalian cell-mediated immunity, dendritic cell maturation, and Toll-like receptor signaling pathways. In vitro and preclinical models investigate its regulatory effects on T-helper cell differentiation, cytotoxic T-lymphocyte activity, and cytokine expression. The compound is supplied exclusively as a reference standard for non-human research applications.
Researchers utilizing analytical research peptides investigate Thymosin Alpha 1 (TA1) to map receptor kinetics, evaluate intracellular signaling cascades, and study host-pathogen interactions in controlled laboratory settings. Understanding the precise biochemical mechanisms of TA1 requires pure, fully characterized peptide samples that undergo rigorous analytical verification.
Thymosin Alpha 1 is a synthetic peptide corresponding to the naturally occurring sequence found in bovine and human thymic tissue. Composed of 28 amino acids (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH), it possesses a molecular weight of approximately 3,108.3 Da. The N-terminal acetylation is critical for structural stability and receptor binding kinetics observed during in vitro experimentation.
In solution, TA1 exhibits a largely unstructured conformation in aqueous buffers, but adopts an alpha-helical structure in the presence of organic solvents or phospholipid membranes. This conformational flexibility is believed to facilitate its interaction with cell surface receptors and membrane-bound complexes. To ensure consistent baseline parameters in structural biology assays, researchers require high-purity Thymosin Alpha 1 free from truncated sequences or residual trifluoroacetate (TFA) salts.
Preclinical investigation into TA1 highlights its primary action through pattern recognition receptors, specifically Toll-like receptor 7 (TLR7) and Toll-like receptor 9 (TLR9), as well as TLR2 in myeloid cells. Binding to these receptors initiates downstream intracellular cascades via the MyD88-dependent signaling pathway, leading to the activation and nuclear translocation of nuclear factor kappa B (NF-κB) and interferon regulatory factor 7 (IRF7).
In vitro assays indicate that activation of these pathways upregulates the transcription of pro-inflammatory and immunomodulatory cytokines, including Interleukin-2 (IL-2), Interleukin-12 (IL-12), and Interferon-gamma (IFN-γ). Furthermore, preclinical models demonstrate that TA1 modulates indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells, suggesting a dual regulatory role capable of suppressing excessive inflammatory cascades under specific experimental conditions. Researchers interested in broader immunomodulatory pathways can consult the PX1 Research Library for comparative molecular datasets.
Laboratory studies involving Thymosin Alpha 1 span several domain areas within immunology and pathology. In murine models of viral challenge, administration of TA1 has been shown to enhance MHC Class I expression on antigen-presenting cells, facilitating more effective recognition by CD8+ cytotoxic T-lymphocytes. In vitro cultures of human peripheral blood mononuclear cells (PBMCs) demonstrate increased proliferation of mature T-cells and elevated natural killer (NK) cell cytotoxicity following TA1 exposure.
Beyond viral immunology models, preclinical research explores TA1 in fungal and bacterial sepsis models. Animal studies indicate that TA1 administration improves survival outcomes in polymicrobial sepsis models by modulating neutrophil function and reducing pulmonary vascular permeability. These preclinical findings provide critical insights into cell-mediated host defense mechanisms, though further baseline research remains ongoing across various target cell lines.
When designing immunological or tissue repair protocols, investigators frequently compare Thymosin Alpha 1 against other regulatory peptides to isolate specific biochemical outcomes. While TA1 acts predominantly as an upstream modulator of T-cell maturation and TLR signaling, related compounds exert distinct cellular effects.
For example, Thymosin Beta-4 regulates actin polymerization and cell migration, making it a focus for cell motility and wound healing assays rather than adaptive immune pathways. Similarly, LL-37 serves as a host defense antimicrobial peptide that directly disrupts bacterial membranes and acts as a chemoattractant, whereas BPC-157 is evaluated primarily in cytoprotection and angiogenesis models. Understanding these functional differences ensures researchers select the exact molecular candidate required for their target receptor profile.
Proper reconstitution techniques are mandatory to maintain peptide integrity and ensure reproducible assay outcomes. Thymosin Alpha 1 is supplied as a sterile, lyophilized cake or powder. Prior to reconstitution, vials should be brought to room temperature inside a desiccated environment to minimize condensation.
For routine cell culture and enzymatic assays, reconstitute the lyophilized powder using sterile target-grade solvents, such as bacteriostatic water, sterile 0.9% sodium chloride, or phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear mechanical agitation such as vigorous vortexing; gently swirl or invert the vial until complete dissolution is achieved. For precise concentration calculations prior to assay dilution, laboratory personnel may utilize the peptide reconstitution calculator.
Lyophilized Thymosin Alpha 1 maintains high chemical stability when stored at -20°C or -80°C in a desiccated, light-protected environment. Under these conditions, the peptide remains stable for up to 24 months without significant hydrolysis or oxidation of key residues.
Once reconstituted into aqueous solution, aliquots should be prepared to avoid repeated freeze-thaw cycles, which induce mechanical degradation and peptide aggregation. Reconstituted stock solutions stored at 4°C are generally stable for up to 7 to 14 days depending on the vehicle sterile condition. For long-term liquid storage, aliquots should be frozen at -80°C and processed immediately upon thawing.
Reproducibility in laboratory research depends directly on reagent purity and batch-to-batch consistency. Substandard research peptides contaminated with truncated deletion sequences, residual solvents, or heavy metals yield erratic bioassay results and false quantitative data.
PX1 Research subjects every lot of Thymosin Alpha 1 to independent, third-party analytical verification within ISO 17025 accredited facilities. Quality testing protocols require Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to guarantee purity exceeding 98.0%, combined with Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight (3,108.3 Da). A lot-specific Certificate of Analysis (COA) is published for every batch, detailing purity percentages, mass spec charts, and lot identification numbers.
In cell culture and immunological assays, endotoxin contamination (lipopolysaccharides derived from Gram-negative bacteria) can prematurely trigger TLR4 activation, invalidating experimental controls and producing false-positive cytokine data. Consequently, verifying low endotoxin limits is critical for valid in vitro research.
PX1 Research peptides are synthesized in state-of-the-art, GMP-compliant facilities located in the United States. Vials undergo standard Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below <0.01 EU/μg. Additionally, sterile filtration protocols (0.22-micron filter processing) and environmental controls ensure high product cleanliness suitable for sensitive cell-line experiments.
Academic institutions, biotechnology organizations, and contract research organizations (CROs) require dependable supply chains and rapid fulfillment to maintain project timelines. Reagent degradation due to extended shipping transit can compromise research continuity.
PX1 Research operates dedicated fulfillment hubs in California and Arizona, providing same-day dispatch for orders placed Monday through Friday before cut-off times. Institutional buyers requiring scaled quantities, bulk sequence synthesis, or custom packaging solutions can explore tailored supply agreements via the PX1 Wholesale Portal.
What is the primary target of Thymosin Alpha 1 in preclinical research?
Preclinical studies demonstrate that Thymosin Alpha 1 acts primarily through Toll-like receptors TLR7, TLR9, and TLR2, downstream activating the MyD88-dependent NF-κB signaling pathway to modulate T-cell proliferation and cytokine expression.
What is the molecular weight and sequence of Thymosin Alpha 1?
Thymosin Alpha 1 has a molecular weight of approximately 3,108.3 Da and consists of a 28-amino acid sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.
How is Thymosin Alpha 1 purity verified by PX1 Research?
PX1 Research verifies purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and confirms molecular identity via Electrospray Ionization Mass Spectrometry (ESI-MS) in ISO 17025 accredited labs, ensuring every lot exceeds 98% purity.
What endotoxin levels are acceptable for Thymosin Alpha 1 in cell culture assays?
To avoid non-specific inflammatory signaling in cell culture, endotoxin levels should be strictly below 0.05 EU/μg. PX1 Research tests every lot to ensure endotoxin content remains below <0.01 EU/μg via LAL assay.
How should lyophilized Thymosin Alpha 1 be stored upon delivery?
Lyophilized powder should be stored at -20°C or -80°C in a dry, light-protected container. Under these conditions, the peptide maintains analytical stability for up to 24 months.
What is the difference between Thymosin Alpha 1 and Thymosin Beta-4?
Thymosin Alpha 1 is an immunomodulatory peptide involved in T-cell differentiation and TLR activation, whereas Thymosin Beta-4 is an actin-sequestering peptide focused on cell migration, cytoskeletal remodeling, and tissue repair models.
How should Thymosin Alpha 1 be reconstituted for laboratory experiments?
Reconstitution should be performed using sterile bacteriostatic water, 0.9% sodium chloride, or PBS (pH 7.4). Avoid high-shear vortexing; gently swirl the vial to completely dissolve the lyophilized powder.
Is Thymosin Alpha 1 approved for human clinical use or administration?
No. Thymosin Alpha 1 provided by PX1 Research is strictly a synthesized research chemical intended exclusively for in vitro and preclinical laboratory research. It is not for human or veterinary administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.